NEW YORK (GenomeWeb News) — WaferGen has completed a reverse merger with WaferGen Bio-systems, a Nevada-based shell company, under which WaferGen backed into WaferGen Bio-systems for an undisclosed sum.  
 
In connection with the deal, the new entity, WaferGen Bio-systems, received a private stock placement worth $10.7 million. The new company’s stock is trading on the Over-the-Counter Bulletin Board under the ticker name WGBS, and was up around 15 percent at $2.30 in afternoon trading today.   
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.